Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.

Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K, Wang J.

Oncogene. 2014 Jun 9. doi: 10.1038/onc.2014.158. Epub 2014 Jun 9. Retraction in: Oncogene. 2014 Aug 28;33(35):4450.

PMID:
24909173
2.

IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway.

Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, Liu B, Su L.

Oncotarget. 2017 Mar 28;8(13):20741-20750. doi: 10.18632/oncotarget.15119.

3.

Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.

Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP.

Cancer Biol Ther. 2011 Nov 15;12(10):924-38. doi: 10.4161/cbt.12.10.17780. Epub 2011 Nov 15.

4.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

5.

Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.

Subramaniam KS, Omar IS, Kwong SC, Mohamed Z, Woo YL, Mat Adenan NA, Chung I.

Am J Cancer Res. 2016 Jan 15;6(2):200-13. eCollection 2016.

6.

Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.

Soon PS, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE, Baxter RC.

Endocr Relat Cancer. 2013 Jan 7;20(1):1-12. doi: 10.1530/ERC-12-0227. Print 2013 Feb.

7.
8.

GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts.

Luo H, Yang G, Yu T, Luo S, Wu C, Sun Y, Liu M, Tu G.

Endocr Relat Cancer. 2014 Mar 7;21(2):355-69. doi: 10.1530/ERC-13-0237. Print 2014 Apr.

9.

Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P.

Clin Cancer Res. 2017 Apr 1;23(7):1710-1721. doi: 10.1158/1078-0432.CCR-15-2851. Epub 2016 Oct 4.

PMID:
27702820
10.
11.

The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.

Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, Joffé EB, Simian M.

Breast Cancer Res Treat. 2012 Jun;133(2):459-71. doi: 10.1007/s10549-011-1766-x. Epub 2011 Sep 21.

12.

Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway.

Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z, Wu X, Zhou Q, Xu K.

Oncotarget. 2017 Jun 28;8(44):76116-76128. doi: 10.18632/oncotarget.18814. eCollection 2017 Sep 29.

13.

GRP78 secreted by tumor cells stimulates differentiation of bone marrow mesenchymal stem cells to cancer-associated fibroblasts.

Peng Y, Li Z, Li Z.

Biochem Biophys Res Commun. 2013 Nov 1;440(4):558-63. doi: 10.1016/j.bbrc.2013.09.108. Epub 2013 Oct 7.

PMID:
24113381
15.

The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma.

Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, Lin YS.

J Pathol. 2013 Oct;231(2):180-9. doi: 10.1002/path.4226. Epub 2013 Aug 12.

PMID:
23775566
16.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

17.

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R.

Breast Cancer Res. 2010;12(3):R40. doi: 10.1186/bcr2594. Epub 2010 Jun 22.

18.

Experimental generation of carcinoma-associated fibroblasts (CAFs) from human mammary fibroblasts.

Polanska UM, Acar A, Orimo A.

J Vis Exp. 2011 Oct 25;(56):e3201. doi: 10.3791/3201.

19.

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.

Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B.

Breast Cancer Res. 2011 May 19;13(3):R52. doi: 10.1186/bcr2883.

20.

Epithelial-stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness.

Angelucci C, Maulucci G, Lama G, Proietti G, Colabianchi A, Papi M, Maiorana A, De Spirito M, Micera A, Balzamino OB, Di Leone A, Masetti R, Sica G.

PLoS One. 2012;7(12):e50804. doi: 10.1371/journal.pone.0050804. Epub 2012 Dec 10.

Supplemental Content

Support Center